50 studies found for:    physical | urticaria
Show Display Options
RSS Create an RSS feed from your search for:
physical | urticaria
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Pathogenesis of Physical Induced Urticarial Syndromes
Conditions: Autoinflammatory Syndromes;   Physical Urticaria
Intervention:
2 Recruiting Cold Urticaria Treatment With Xolair
Condition: Cold Contact Urticaria
Interventions: Drug: Omalizumab;   Drug: Placebo
3 Completed
Has Results
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
Condition: Chronic Urticaria
Interventions: Drug: Omalizumab 75-375 mg;   Drug: Placebo to omalizumab;   Drug: Loratadine;   Drug: Clemastine
4 Completed
Has Results
Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P05634)
Conditions: Rhinitis, Allergic, Seasonal;   Rhinitis, Allergic, Perennial;   Urticaria
Intervention: Drug: Desloratadine Syrup
5 Completed Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
Condition: Urticaria
Interventions: Drug: Bilastine;   Drug: Levocetirizine;   Drug: Placebo
6 Recruiting Urticaria Facticia Treatment With Omalizumab (UFO)
Condition: Symptomatic Dermographism
Interventions: Drug: Omalizumab;   Drug: Placebo
7 Completed
Has Results
Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
Condition: Idiopathic Solar Urticaria
Interventions: Drug: Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209);   Drug: Ti02 pigmentary 3% alone (formula RV3131A-MV1211);   Drug: bisoctrizole 10% alone (formula RV3131A-MV1237);   Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213);   Drug: Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329);   Drug: Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212);   Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)];   Drug: V0096 CR vehicle (formula RV3131A-MV1197)
8 Not yet recruiting Efficacy and Safety of Omalizumab in Patients With Severe Acute Urticaria
Condition: Urticaria
Intervention: Drug: omalizumab
9 Recruiting Studies of the Natural History and Pathogenesis and Outcome of Neonatal Onset Multisystem Inflammatory Disease (NOMID/CAPS, DIRA, CRMO, Still s Disease, Behcet s Disease, and Other Undifferentiated Autoinflammatory Diseases)
Conditions: Urticaria;   Arthropathy;   Lymphadenopathy;   Nervous System Anomalies
Intervention:
10 Suspended Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
Conditions: Nervous System Malformations;   Arthropathy, Neurogenic;   Urticaria;   Papilledema
Intervention:
11 Terminated Efficacy of Rupatadine 5, 10 and 20 Mg in Chronic Idiopathic Urticaria
Condition: Urticaria
Intervention: Drug: RUPATADINE (ANTI-HISTAMINE)
12 Completed Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses
Conditions: Urticaria;   Vasculitis
Intervention: Drug: canakinumab
13 Completed An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)
Condition: Urticaria
Intervention: Drug: Desloratadine
14 Recruiting Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Conditions: Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue;   Pyoderma Gangrenosum;   Erosive Pustular Dermatosis of the Scalp;   Sweet's Syndrome;   Behcet's Disease;   Bowel-associated Dermatosis-arthritis Syndrome;   Pustular Psoriasis;   Acute Generalized Exanthematous Pustulosis;   Keratoderma Blenorrhagicum;   Sneddon-Wilkinson Disease;   IgA Pemphigus;   Amicrobial Pustulosis of the Folds;   Infantile Acropustulosis;   Transient Neonatal Pustulosis;   Neutrophilic Eccrine Hidradenitis;   Rheumatoid Neutrophilic Dermatitis;   Neutrophilic Urticaria;   Still's Disease;   Erythema Marginatum;   Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes;   Dermatitis Herpetiformis;   Linear IgA Bullous Dermatosis;   Bullous Systemic Lupus Erythematosus;   Inflammatory Epidermolysis Bullosa Aquisita;   Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis);   Small Vessel Vasculitis Including Urticarial Vasculitis;   Erythema Elevatum Diutinum;   Medium Vessel Vasculitis
Intervention: Procedure: Collection of biological samples
15 Completed Bilastine Updosing - Characterization of Underlying Mechanisms
Condition: Cold Contact Urticaria
Intervention: Drug: Bilastine
16 Active, not recruiting A Long-Term Examination of Asthma From Childhood Through Adolescence
Conditions: Asthma;   Dermatitis, Atopic;   Rhinitis;   Urticaria
Intervention:
17 Completed Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria
Condition: Urticaria
Interventions: Drug: Cetirizine;   Drug: Desloratadine;   Drug: Fexofenadine;   Drug: Ebastine;   Drug: Bilastine
18 Recruiting Bilastine Updosing in Chronic Spontaneous Urticaria
Condition: Chronic Urticaria
Interventions: Drug: Bilastine;   Drug: Bilastin
19 Completed Phase II Solar Urticaria (SU) Pilot Study
Condition: Solar Urticaria
Intervention: Drug: afamelanotide
20 Recruiting Cold Contact Urticaria Treatment With Rilonacept
Condition: Cold Contact Urticaria
Interventions: Drug: Rilonacept;   Drug: Placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years